Home » Stocks » AHAC

Alpha Healthcare Acquisition Corp. (AHAC)

Stock Price: $10.34 USD -0.05 (-0.48%)
Updated Jun 16, 2021 10:29 AM EDT - Market open
Market Cap 137.29M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 10.36M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $10.34
Previous Close $10.39
Change ($) -0.05
Change (%) -0.48%
Day's Open 10.43
Day's Range 10.32 - 10.45
Day's Volume 23,822
52-Week Range 9.65 - 16.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million.  Humacyte founder and ...

3 weeks ago - Benzinga

NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...

Other stocks mentioned: AHACU
2 months ago - PRNewsWire

They could even deliver greater gains than just a 10-times return.

Other stocks mentioned: GHVIU
3 months ago - The Motley Fool

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today ...

3 months ago - GlobeNewsWire

The biotech is going public through the special acquisition company (SPAC).

3 months ago - The Motley Fool

DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today ...

3 months ago - GlobeNewsWire

Why Humacyte Is Going Public Via SPAC

YouTube video

Feb.17 -- Dr. Laura Niklason, chief executive officer and founder of Humacyte, discusses the biotech company's decision to go public through a merger with Alpha Healthcare Acquisition Corp., a special p...

3 months ago - Bloomberg Technology

Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.

3 months ago - The Motley Fool

NEW YORK and DURHAM, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced ex...

Other stocks mentioned: AHACU
3 months ago - GlobeNewsWire

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the “Company”) announced today that holders of the units sold in the Company's initial public offering of 10,000,000 units...

Other stocks mentioned: AHACU
7 months ago - GlobeNewsWire

New York, NY, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ: AHACU) (the “Company”) announced today that it closed its initial public offering of 10,000,000 units at a ...

Other stocks mentioned: AHACU
8 months ago - GlobeNewsWire

New York, NY, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 10,000,000 units at $10.00 per unit. T...

Other stocks mentioned: AHACU
8 months ago - GlobeNewsWire

About AHAC

Alpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Industry
Shell Companies
IPO Date
Sep 18, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AHAC
Full Company Profile